Delveinsight oncology based Reports

Jul 17, 2018

Keytruda, the First Anti-PD-1 Therapy for Advanced Melanoma, Approved in China Merck announced that Keytruda, Merck’s anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior lin...

Jul 30, 2015

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA).DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 has received great response and feedback from client...